{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:42:47Z","timestamp":1777621367324,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12185-022-03334-8","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T06:10:56Z","timestamp":1649398256000},"page":"89-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy"],"prefix":"10.1007","volume":"116","author":[{"given":"Chikashi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Katsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Taneike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Garbayo Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"3334_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12929-020-00674-7","volume":"27","author":"HA Hou","year":"2020","unstructured":"Hou HA, Tien HF. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J Biomed Sci. 2020;27:81.","journal-title":"J Biomed Sci"},{"key":"3334_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"3334_CR3","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML) 2020 [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"3334_CR4","unstructured":"Cancer Information Service NCC, Japan. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. 2016. Available from: https:\/\/ganjoho.jp\/public\/cancer\/CLL\/."},{"key":"3334_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72.","journal-title":"J Hematol Oncol"},{"key":"3334_CR6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119:2720\u20137.","journal-title":"Cancer"},{"key":"3334_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10147-019-01467-1","volume":"24","author":"K Miyamoto","year":"2019","unstructured":"Miyamoto K, Minami Y. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. Int J Clin Oncol. 2019;24:893\u20138.","journal-title":"Int J Clin Oncol"},{"key":"3334_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010120","author":"R Palmieri","year":"2020","unstructured":"Palmieri R, Paterno G, De Bellis E, Mercante L, Buzzatti E, Esposito F, et al. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12010120.","journal-title":"Cancers (Basel)."},{"key":"3334_CR9","first-page":"2021","volume":"2","author":"National Comprehensive Cancer Network","year":"2020","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Acute Myeloid Leukemia. 2020;2:2021.","journal-title":"Acute Myeloid Leukemia"},{"key":"3334_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:697\u2013712.","journal-title":"Ann Oncol"},{"key":"3334_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12185-020-02856-3","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Yamaguchi H, Maeda Y, Yamauchi T. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML). Int J Hematol. 2020;111:595\u2013613.","journal-title":"Int J Hematol"},{"key":"3334_CR12","first-page":"151","volume":"82","author":"T Naoe","year":"2020","unstructured":"Naoe T. Editors\u2019 choice how to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya J Med Sci. 2020;82:151\u201360.","journal-title":"Nagoya J Med Sci"},{"key":"3334_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46.","journal-title":"J Hematol Oncol"},{"key":"3334_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.leukres.2015.12.013","volume":"42","author":"D Minakata","year":"2016","unstructured":"Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82\u20137.","journal-title":"Leuk Res"},{"key":"3334_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3109\/10428194.2014.963074","volume":"56","author":"J Jin","year":"2015","unstructured":"Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, et al. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia. Leuk Lymphoma. 2015;56:1691\u20137.","journal-title":"Leuk Lymphoma"},{"key":"3334_CR16","unstructured":"MHLW approval of Vidaza\u00ae (azacitidine) for the treatment of acute myeloid leukemia. [press release]. 2021."},{"key":"3334_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139.","journal-title":"Blood"},{"key":"3334_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34:972\u20139.","journal-title":"J Clin Oncol"},{"key":"3334_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.clml.2016.08.006","volume":"16","author":"E Ma","year":"2016","unstructured":"Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, et al. An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices. Clin Lymphoma Myeloma Leuk. 2016;16:625-36 e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3334_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","volume":"94","author":"BC Medeiros","year":"2015","unstructured":"Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94:1127\u201338.","journal-title":"Ann Hematol"},{"key":"3334_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"3334_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","volume":"17","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Dohner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017;17:852.","journal-title":"BMC Cancer"},{"key":"3334_CR23","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"3334_CR24","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"issue":"7","key":"3334_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei A, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med."},{"key":"3334_CR26","doi-asserted-by":"publisher","first-page":"e4182","DOI":"10.1097\/MD.0000000000004182","volume":"95","author":"Y Chen","year":"2016","unstructured":"Chen Y, Yang T, Zheng X, Yang X, Zheng Z, Zheng J, et al. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy. Medicine (Baltimore). 2016;95:e4182.","journal-title":"Medicine (Baltimore)"},{"key":"3334_CR27","doi-asserted-by":"publisher","first-page":"e12102","DOI":"10.1097\/MD.0000000000012102","volume":"97","author":"J Xu","year":"2018","unstructured":"Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study. Medicine (Baltimore). 2018;97:e12102.","journal-title":"Medicine (Baltimore)"},{"key":"3334_CR28","unstructured":"Venclexta PI (Japanese label). 2021."},{"key":"3334_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/ejh.13205","volume":"102","author":"JD Griffin","year":"2019","unstructured":"Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: a medical chart study. Eur J Haematol. 2019;102:341\u201350.","journal-title":"Eur J Haematol"},{"key":"3334_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2002321","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, et al. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leuk Lymphoma. 2022. https:\/\/doi.org\/10.1080\/10428194.2021.2002321.","journal-title":"Leuk Lymphoma."},{"key":"3334_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"3334_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12185-017-2303-4","volume":"106","author":"S Miyawaki","year":"2017","unstructured":"Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310\u201325.","journal-title":"Int J Hematol"},{"key":"3334_CR33","volume-title":"Patterns of healthcare resource utilization (HRU) in unfit patients with acute myeloid leukemia (AML) receiving first-line systemic treatment or best supportive care (BSC): a multicenter international study (CURRENT)","author":"T Ito","year":"2021","unstructured":"Ito T, Sanford D, Tomuleasa C, Hsiao H-H, Enciso Olivera L, Enjeti A, et al. Patterns of healthcare resource utilization (HRU) in unfit patients with acute myeloid leukemia (AML) receiving first-line systemic treatment or best supportive care (BSC): a multicenter international study (CURRENT). Lawrenceville: ISPOR; 2021."},{"key":"3334_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","volume":"21","author":"EM Stein","year":"2018","unstructured":"Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ. 2018;21:556\u201363.","journal-title":"J Med Econ"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03334-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T17:01:52Z","timestamp":1656003712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3334"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03334-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. Yoshida: Investigator on AbbVie-funded clinical study. Honoraria from Bristol Myers Squibb, Novartis Pharma KK, Pfizer Japan Inc., Otsuka Pharmaceutical., AbbVie, Janssen Pharmaceutical KK, Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd. Research funding from Bristol Myers Squibb. T. Kondo: Advisory role for Astellas Pharma, Otsuka Pharmaceutical. Honoraria from Astellas Pharma, Bristol Myers Squibb, Otsuka Pharmaceutical, Novartis, and Sumitomo Dainippon Pharma. T. Ito: Research funding from AbbVie and Bristol Myers Squibb. Honoraria from AbbVie, Bristol Myers Squibb, Takeda Pharmaceutical Sanofi, CSL Behring, and Novartis. M. Kizaki, Y. Morita, T. Eto, Y. Katsuoka, N. Takezako, N. Uoshima, J. Ando, A. Mori, A. Satake, J. Watanabe: No potential conflicts of interest are reported. K. Yamamoto, T. Komeno: Investigator on AbbVie-funded clinical study. T. Miyamoto: Honoraria from AbbVie, Astellas Pharmaceutical, Astellas Amgen Pharmaceutical, Bristol Myers Squibb, Celgene, Merck Sharp & Dohme, Otsuka Pharmaceutical, and Takeda Pharmaceutical. K. Imada: Honoraria from Astellas Pharma, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, and Takeda Pharmaceutical. Y. Ishikawa: Personal fees from AbbVie, Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo, FUJIFILM, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, and Pfizer. Y. Kawakami, T. Morita, I. Taneike, M. Nakayama, Y. Duan, B. Garbayo Guijarro, A. Delgado, C. Llamas: Employees of AbbVie and may hold stock or options. H. Kiyoi: Research funding from AbbVie, Astellas Pharma, Bristol Myers Squibb, Chugai Pharmaceutical, CURED Inc., Daiichi Sankyo, Eisai, FUJIFILM, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, Perseus Proteomics, Pfizer, Sanofi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Zenyaku Kogyo. Honoraria from Astellas Pharma, Bristol Myers Squibb, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}